Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)

Cancer Immunology, Immunotherapy : CII
Sabine SchmidMartin Früh

Abstract

Response to immune checkpoint inhibitors depends on tumor intrinsic properties and also on host factors in the tumour microenvironment including the presence of immune cells (IC). We hypothesized that nivolumab efficacy varies across different metastatic sites. We retrospectively analyzed computed tomography scans of patients with metastatic non-small cell lung carcinoma (NSCLC) receiving nivolumab. RECIST 1.1 criteria were applied to assess the overall response rate (ORR) and organ-specific response rate (OSRR). We analyzed 52 patients including 44% females, 58% adenocarcinoma and 8% never smokers. Involved organs had target-lesions in the lung (42%), liver (25%), lymph nodes (56%) and soft tissue (13%) and non-target lesions in the bones (23%). ORR and disease control rate (DCR) were 20% and 45%, respectively. Median overall survival, progression-free survival and duration of response were 11.9, 2.3 and 10.3 months. OSRR and organ-specific DCR (OSDCR) were 28% and 90% in lymph nodes, 8% and 54 in the liver, and 9% and 55% in lung metastases. Nine out of 12 patients with bone metastases had progressive lesions. The cumulative incidence probability of organ-specific progression at 6 months was 14% in lymph nodes, 42% in the liv...Continue Reading

References

Jan 18, 2003·Endocrine Research·S R Bornstein, H Rutkowski
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Nov 17, 2012·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Andrew J WeickhardtD Ross Camidge
Apr 23, 2013·Cellular & Molecular Immunology·Fenglei Li, Zhigang Tian
Dec 19, 2014·Nature Immunology
Dec 30, 2014·Molecular and Cellular Endocrinology·Waldemar KanczkowskiStefan R Bornstein
Feb 20, 2015·Molecular Cancer Therapeutics·Sandip Pravin Patel, Razelle Kurzrock
Apr 4, 2015·Science·Padmanee Sharma, James P Allison
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Aug 15, 2015·Cancer Discovery·Antoni Ribas
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Oct 25, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Klazien Matter-WalstraUNKNOWN Swiss Group for Clinical Cancer Research
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Dec 27, 2016·Journal for Immunotherapy of Cancer·Mizuki NishinoMark M Awad
Jan 20, 2017·Nature·Daniel S Chen, Ira Mellman
Apr 12, 2017·Nature·Alexander C HuangE John Wherry
Jun 22, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P N AguiarG L Lopes

❮ Previous
Next ❯

Citations

Jun 2, 2020·Expert Review of Anticancer Therapy·Maddalena DoniniMatteo Santoni
Nov 23, 2019·Journal for Immunotherapy of Cancer·Lorenza LandiFederico Cappuzzo
Apr 29, 2020·Cancers·Stephan RheinheimerPetros Christopoulos
Oct 4, 2020·Science Immunology·James C LeeJeffrey A Bluestone
May 20, 2020·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·V FormicaH T Arkenau
Nov 17, 2020·Frontiers in Oncology·Sergi BenaventeJuan Lorente
Feb 3, 2021·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Florian EichhornMartin E Eichhorn
Apr 6, 2021·Frontiers in Oncology·Hyunjong LeeHongyoon Choi
Jun 3, 2021·Cancers·Ling PengZibing Wang
Jun 10, 2021·Expert Opinion on Investigational Drugs·D Brock HewittTimothy M Pawlik
Jan 7, 2022·Annals of Surgical Oncology·Lauren N KrumeichHeather Wachtel
Jan 15, 2022·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Einat Cinnamon, Eli Pikarsky

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.